CPMV (Mosaic ImmunoEngineering) Total Stockholders Equity: $-7.83 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Mosaic ImmunoEngineering Total Stockholders Equity?

Mosaic ImmunoEngineering CPMV Total Stockholders Equity is $-7.83 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Mosaic ImmunoEngineering's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-7.83 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Mosaic ImmunoEngineering's Book Value per Share for the quarter that ended in Jun. 2026 was $-1.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Mosaic ImmunoEngineering's Debt-to-Equity for the quarter that ended in Jun. 2026 was -0.22.

Mosaic ImmunoEngineering  (OTCPK:CPMV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Mosaic ImmunoEngineering's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-7.829-0)/7.242
=-1.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Mosaic ImmunoEngineering's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.2 + 1.502) / -7.829
=-0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mosaic ImmunoEngineering Total Stockholders Equity Related Terms

Mosaic ImmunoEngineering Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Mosaic ImmunoEngineering's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mosaic ImmunoEngineering Total Stockholders Equity Chart

Mosaic ImmunoEngineering Annual Data
Trend May16 May17 May18 May19 May20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.80 -4.89 -5.87 -6.79 -7.48

Mosaic ImmunoEngineering Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.14 -7.31 -7.48 -7.65 -7.83
What does a Total Stockholders Equity of $-7.83 Mil mean?
Mosaic ImmunoEngineering (CPMV) has a Total Stockholders Equity of $-7.83 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Mosaic ImmunoEngineering and its competitors.
Is Mosaic ImmunoEngineering's Total Stockholders Equity too high?
Mosaic ImmunoEngineering's current Total Stockholders Equity is $-7.83 Mil.
How does Mosaic ImmunoEngineering's Total Stockholders Equity compare to TCRT and JAGX?
Mosaic ImmunoEngineering's Total Stockholders Equity of $-7.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Mosaic ImmunoEngineering and its competitors. Mosaic ImmunoEngineering's current Total Stockholders Equity is $-7.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mosaic ImmunoEngineering stock overvalued right now?
Mosaic ImmunoEngineering (CPMV) has a current Total Stockholders Equity of $-7.83 Mil. The current Total Stockholders Equity is $-7.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Mosaic ImmunoEngineering (CPMV), the current Total Stockholders Equity is $-7.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mosaic ImmunoEngineering Business Description

Address 9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions. The company is pursuing new product candidates and platforms to build a product pipeline based on its deep understanding of immunotherapies.